Advertisement

Sex and Gender Differences in Gastroenterology and Hepatology

  • Matteo Garcovich
  • Andrew Kenneth Burroughs
Chapter

Abstract

Sex and gender differences regarding the epidemiology, clinical features, natural history, and response to therapies in hepatology and gastroenterology may be of major relevance for clinical medicine but have not yet been studied in detail so far. The mechanisms of sex or gender differences in these fields and their clinical implications are still unclear.

Keywords

Inflammatory Bowel Disease Ulcerative Colitis Sustained Virological Response Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Reuben A. A sheep in wolf’s clothing. Hepatology. 2003;38:1596-1601.PubMedCrossRefGoogle Scholar
  2. 2.
    Alvarez F. Autoimmune hepatitis and primary sclerosing cholangitis. Clin Liver Dis. 2006;10:89-107, vi.PubMedCrossRefGoogle Scholar
  3. 3.
    Sherlock S, Dooley J. Diseases of the Liver and Biliary System. London: Blackwell; 2002.Google Scholar
  4. 4.
    Nalbandian G, Van de Water J, Gish R, et al. Is there a serological difference between men and women with primary biliary cirrhosis? Am J Gastroenterol. 1999;94:2482-2486.PubMedCrossRefGoogle Scholar
  5. 5.
    Myers RP, Shaheen AA, Fong A, et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology. 2009;50:1884-1892.PubMedCrossRefGoogle Scholar
  6. 6.
    Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989;10:430-436.PubMedCrossRefGoogle Scholar
  7. 7.
    Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125: 1364-1369.PubMedCrossRefGoogle Scholar
  8. 8.
    Babes VT, Blana D, Duiculescu D, Cepanaru S. Investigations on HBe antigen. Note III. HBe system and sex-dependent clearance of HBsAg subtypes. Virologie. 1981;32:261-268.PubMedGoogle Scholar
  9. 9.
    Babes VT, Lenkei R, Steiner N, Berca C. Apparently healthy HBsAg carriers: sex-dependent difference in ABO blood group distribution, subtype ratio and antigen titer. Virologie. 1978;29:3-8.PubMedGoogle Scholar
  10. 10.
    Blumberg BS. Sex differences in response to hepatitis B virus. I. History. Arthritis Rheum. 1979;22:1261-1266.PubMedCrossRefGoogle Scholar
  11. 11.
    London WT, Drew JS. Sex differences in response to hepatitis B infection among patients receiving chronic dialysis treatment. Proc Natl Acad Sci USA. 1977;74:2561-2563.PubMedCrossRefGoogle Scholar
  12. 12.
    Robinson T, Bullen C, Humphries W, Hornell J, Moyes C. The New Zealand hepatitis B screening programme: screening coverage and prevalence of chronic hepatitis B infection. N Z Med J. 2005;118:U1345.PubMedGoogle Scholar
  13. 13.
    Chu CM, Liaw YF, Sheen IS, Lin DY, Huang MJ. Sex difference in chronic hepatitis B virus infection: an appraisal based on the status of hepatitis B e antigen and antibody. Hepatology. 1983;3:947-950.PubMedCrossRefGoogle Scholar
  14. 14.
    Chu CM, Sheen IS, Lin SM, Liaw YF. Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers. Clin Infect Dis. 1993;16:709-713.PubMedCrossRefGoogle Scholar
  15. 15.
    Woolf IL, El Sheikh N, Cullens H, et al. Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B. Br Med J. 1976;2:669-671.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang N, Zheng Y, Yu X, Lin W, Chen Y, Jiang Q. Sex-modified effect of hepatitis B virus infection on mortality from primary liver cancer. Am J Epidemiol. 2009;169:990-995.PubMedCrossRefGoogle Scholar
  17. 17.
    Hislop TG, Teh C, Low A, et al. Hepatitis B knowledge, testing and vaccination levels in Chinese immigrants to British Columbia, Canada. Can J Public Health. 2007;98: 125-129.PubMedGoogle Scholar
  18. 18.
    Bar-Shany S, Green MS, Slepon R, Shinar E. Ethnic differences in the prevalence of anti-hepatitis C antibodies and hepatitis B surface antigen in Israeli blood donors by age, sex, country of birth and origin. J Viral Hepat. 1995;2:139-144.PubMedCrossRefGoogle Scholar
  19. 19.
    Chu CM, Lin SM, Hsieh SY, et al. Etiology of sporadic acute viral hepatitis in Taiwan: the role of hepatitis C virus, hepatitis E virus and GB virus-C/hepatitis G virus in an endemic area of hepatitis A and B. J Med Virol. 1999;58:154-159.PubMedCrossRefGoogle Scholar
  20. 20.
    Tang S. Seroepidemiological study on hepatitis C virus infection among blood donors from various regions in China. Zhonghua Liu Xing Bing Xue Za Zhi. 1993;14:271-274.PubMedGoogle Scholar
  21. 21.
    DuBois DB, Gretch D, dela Rosa C, et al. Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: gender-related differences in viral load. Am J Kidney Dis. 1994;24:795-801.PubMedGoogle Scholar
  22. 22.
    Kang SY, Goldstein MF, Deren S. Gender differences in health status and care among HIV-infected minority drug users. AIDS Care. 2008;20:1146-1151.PubMedCrossRefGoogle Scholar
  23. 23.
    Rodriguez-Torres M, Rios-Bedoya CF, Rodriguez-Orengo J, et al. Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender. J Clin Gastroenterol. 2006;40:358-366.PubMedCrossRefGoogle Scholar
  24. 24.
    Evans JL, Hahn JA, Page-Shafer K, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003;80:137-146.PubMedCrossRefGoogle Scholar
  25. 25.
    Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology. 2002;36:S220-S225.PubMedCrossRefGoogle Scholar
  26. 26.
    Hassan MM, Spitz MR, Thomas MB, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer. 2008;123:1883-1891.PubMedCrossRefGoogle Scholar
  27. 27.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.PubMedCrossRefGoogle Scholar
  28. 28.
    Yu MC, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst. 1991;83:1820-1826.PubMedCrossRefGoogle Scholar
  29. 29.
    Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121-124.PubMedCrossRefGoogle Scholar
  30. 30.
    Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32:225-237.PubMedCrossRefGoogle Scholar
  31. 31.
    Giannitrapani L, Soresi M, La Spada E, Cervello M, D’Alessandro N, Montalto G. Sex hormones and risk of liver tumor. Ann N Y Acad Sci. 2006;1089:228-236.PubMedCrossRefGoogle Scholar
  32. 32.
    Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J (Clin Res Ed). 1986;292:1355-1357.CrossRefGoogle Scholar
  33. 33.
    Forman D, Vincent TJ, Doll R. Cancer of the liver and the use of oral contraceptives. Br Med J (Clin Res Ed). 1986;292:1357-1361.CrossRefGoogle Scholar
  34. 34.
    Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127:S72-S78.PubMedCrossRefGoogle Scholar
  35. 35.
    Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA. Gender-related differences in the clinical course of Crohn’s disease. Am J Gastroenterol. 2001;96:1541-1546.PubMedCrossRefGoogle Scholar
  36. 36.
    Loffler A, Glados M. Data on the epidemiology of Crohn disease in the city of Cologne. Med Klin (Munich). 1993;88:516-519.Google Scholar
  37. 37.
    Kildebo S, Nordgaard K, Aronsen O, Breckan R, Burhol PG, Jorde R. The incidence of ulcerative colitis in Northern Norway from 1983 to 1986. The Northern Norwegian Gastroenterology Society. Scand J Gastroenterol. 1990;25: 890-896.PubMedCrossRefGoogle Scholar
  38. 38.
    Ashley MJ. Smoking and diseases of the gastrointestinal system: an epidemiological review with special reference to sex differences. Can J Gastroenterol. 1997;11:345-352.PubMedGoogle Scholar
  39. 39.
    Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol. 2004;2:41-48.PubMedCrossRefGoogle Scholar
  40. 40.
    Brenner H, Hoffmeister M, Arndt V, Haug U. Gender differences in colorectal cancer: implications for age at initiation of screening. Br J Cancer. 2007;96:828-831.PubMedCrossRefGoogle Scholar
  41. 41.
    Gao RN, Neutel CI, Wai E. Gender differences in colorectal cancer incidence, mortality, hospitalizations and surgical procedures in Canada. J Public Health (Oxf). 2008;30:194-201.CrossRefGoogle Scholar
  42. 42.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.PubMedCrossRefGoogle Scholar
  43. 43.
    DeCosse JJ, Ngoi SS, Jacobson JS, Cennerazzo WJ. Gender and colorectal cancer. Eur J Cancer Prev. 1993;2:105-115.PubMedCrossRefGoogle Scholar
  44. 44.
    Alley PG, McNee RK. Age and sex differences in right colon cancer. Dis Colon Rectum. 1986;29:227-229.PubMedCrossRefGoogle Scholar
  45. 45.
    Vobecky J, Leduc C, Devroede G. Sex differences in the changing anatomic distribution of colorectal carcinoma. Cancer. 1984;54:3065-3069.PubMedCrossRefGoogle Scholar
  46. 46.
    dos Santos Silva I, Swerdlow AJ. Sex differences in the risks of hormone-dependent cancers. Am J Epidemiol. 1993;138: 10-28.PubMedGoogle Scholar
  47. 47.
    Kupfer SS, McCaffrey S, Kim KE. Racial and gender disparities in hereditary colorectal cancer risk assessment: the role of family history. J Cancer Educ. 2006;21:S32-S36.PubMedCrossRefGoogle Scholar
  48. 48.
    McQueen A, Vernon SW, Meissner HI, Rakowski W. Risk perceptions and worry about cancer: does gender make a difference? J Health Commun. 2008;13:56-79.PubMedCrossRefGoogle Scholar
  49. 49.
    Boutron-Ruault MC, Senesse P, Faivre J, Chatelain N, Belghiti C, Meance S. Foods as risk factors for colorectal cancer: a case-control study in Burgundy (France). Eur J Cancer Prev. 1999;8:229-235.PubMedCrossRefGoogle Scholar
  50. 50.
    Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med. 2009;6(Suppl 1):60-75.PubMedCrossRefGoogle Scholar
  51. 51.
    Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am. 2002;31:925-943.PubMedCrossRefGoogle Scholar
  52. 52.
    Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914-923.PubMedCrossRefGoogle Scholar
  53. 53.
    Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603-1613.PubMedCrossRefGoogle Scholar
  54. 54.
    Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574-582.PubMedCrossRefGoogle Scholar
  55. 55.
    Lapierre P, Beland K, Martin C, Alvarez F, Alvarez F. Forkhead box p3+ regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis. Hepatology. 2010;51:1789-1798.PubMedCrossRefGoogle Scholar
  56. 56.
    Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003;362:53-61.PubMedCrossRefGoogle Scholar
  57. 57.
    Parikh-Patel A, Gold E, Utts J, Gershwin ME. The association between gravidity and primary biliary cirrhosis. Ann Epidemiol. 2002;12:264-272.PubMedCrossRefGoogle Scholar
  58. 58.
    Tanaka A, Lindor K, Gish R, et al. Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. Hepatology. 1999;30:833-838.PubMedCrossRefGoogle Scholar
  59. 59.
    Corpechot C, Barbu V, Chazouilleres O, Poupon R. Fetal microchimerism in primary biliary cirrhosis. J Hepatol. 2000;33:696-700.PubMedCrossRefGoogle Scholar
  60. 60.
    Fanning PA, Jonsson JR, Clouston AD, et al. Detection of male DNA in the liver of female patients with primary biliary cirrhosis. J Hepatol. 2000;33:690-695.PubMedCrossRefGoogle Scholar
  61. 61.
    Invernizzi P, De Andreis C, Sirchia SM, et al. Blood fetal microchimerism in primary biliary cirrhosis. Clin Exp Immunol. 2000;122:418-422.PubMedCrossRefGoogle Scholar
  62. 62.
    Stevens AM, McDonnell WM, Mullarkey ME, Pang JM, Leisenring W, Nelson JL. Liver biopsies from human females contain male hepatocytes in the absence of transplantation. Lab Invest. 2004;84:1603-1609.PubMedCrossRefGoogle Scholar
  63. 63.
    DeLoia JA, Burk RD, Gearhart JD. Developmental regulation of hepatitis B surface antigen expression in two lines of hepatitis B virus transgenic mice. J Virol. 1989;63:4069-4073.PubMedGoogle Scholar
  64. 64.
    Alward WL, McMahon BJ, Hall DB, Heyward WL, Francis DP, Bender TR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis. 1985;151: 604-609.PubMedCrossRefGoogle Scholar
  65. 65.
    Zacharakis GH, Koskinas J, Kotsiou S, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol. 2005;77:173-179.PubMedCrossRefGoogle Scholar
  66. 66.
    Grossman CJ. Interactions between the gonadal steroids and the immune system. Science. 1985;227:257-261.PubMedCrossRefGoogle Scholar
  67. 67.
    Lawrence T, Hageman T, Balkwill F. Cancer. Sex, cytokines, and cancer. Science. 2007;317:51-52.PubMedCrossRefGoogle Scholar
  68. 68.
    Wang Y, Cui F, Lv Y, et al. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology. 2004;39:318-324.PubMedCrossRefGoogle Scholar
  69. 69.
    Rogers AB, Theve EJ, Feng Y, et al. Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res. 2007;67:11536-11546.PubMedCrossRefGoogle Scholar
  70. 70.
    Rossini GP, Baldini GM, Villa E, Manenti F. Characterization of estrogen receptor from human liver. Gastroenterology. 1989;96:1102-1109.PubMedGoogle Scholar
  71. 71.
    Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998;352:17-20.Google Scholar
  72. 72.
    Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol. 2000;95:218-222.PubMedCrossRefGoogle Scholar
  73. 73.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-1022. doi: 10.1002/hep. 24199.PubMedCrossRefGoogle Scholar
  74. 74.
    Yu MW, Chang HC, Chang SC, et al. Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology. 2003;38:1393-1400.PubMedGoogle Scholar
  75. 75.
    Yu MW, Yang YC, Yang SY, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst. 2001;93:1644-1651.PubMedCrossRefGoogle Scholar
  76. 76.
    Sung YM, Tang NL, Lai PB, Chan PK, Chan FK. Re: Hormonal markers and hepatitis B virus-related ­hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst. 2003;95:559-560.PubMedCrossRefGoogle Scholar
  77. 77.
    Takemoto N, Iizuka N, Yamada-Okabe H, et al. Sex-based molecular profiling of hepatitis C virus-related hepatocellular carcinoma. Int J Oncol. 2005;26:673-678.PubMedGoogle Scholar
  78. 78.
    Hammond C, Jeffers L, Carr BI, Simon D. Multiple genetic alterations, 4q28, a new suppressor region, and potential gender differences in human hepatocellular carcinoma. Hepatology. 1999;29:1479-1485.PubMedCrossRefGoogle Scholar
  79. 79.
    Gustafsson JA, Eneroth P, Hokfelt T, Mode A, Norstedt G, Skett P. Role of the hypothalamo-pituitary-liver axis in sex differences in susceptibility of the liver to toxic agents. Environ Health Perspect. 1981;38:129-141.PubMedCrossRefGoogle Scholar
  80. 80.
    Hernberg S, Kauppinen T, Riala R, Korkala ML, Asikainen U. Increased risk for primary liver cancer among women exposed to solvents. Scand J Work Environ Health. 1988;14:356-365.PubMedGoogle Scholar
  81. 81.
    D’Amour M, Charbonneau M. Sex-related difference in hepatic glutathione conjugation of hexachlorobenzene in the rat. Toxicol Appl Pharmacol. 1992;112:229-234.PubMedCrossRefGoogle Scholar
  82. 82.
    Hampe J, Shaw SH, Saiz R, et al. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet. 1999;65:1647-1655.PubMedCrossRefGoogle Scholar
  83. 83.
    Vermeire S, Satsangi J, Peeters M, et al. Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. Gastroenterology. 2001;120:834-840.PubMedCrossRefGoogle Scholar
  84. 84.
    Fisher SA, Hampe J, Macpherson AJ, et al. Sex stratification of an inflammatory bowel disease genome search shows male-specific linkage to the HLA region of chromosome 6. Eur J Hum Genet. 2002;10:259-265.PubMedCrossRefGoogle Scholar
  85. 85.
    Friedrichs F, Brescianini S, Annese V, et al. Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Hum Genet. 2006;119:305-311.PubMedCrossRefGoogle Scholar
  86. 86.
    Browning BL, Annese V, Barclay ML, et al. Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. J Med Genet. 2008;45:36-42.PubMedCrossRefGoogle Scholar
  87. 87.
    Biank V, Friedrichs F, Babusukumar U, et al. DLG5 R30Q variant is a female-specific protective factor in pediatric onset Crohn’s disease. Am J Gastroenterol. 2007;102:391-398.PubMedCrossRefGoogle Scholar
  88. 88.
    Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet. 1996;347:1212-1217.PubMedCrossRefGoogle Scholar
  89. 89.
    Bouma G, Oudkerk Pool M, Crusius JB, et al. Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn’s disease (CD). Clin Exp Immunol. 1997;109:175-179.PubMedCrossRefGoogle Scholar
  90. 90.
    Paganini-Hill A. Estrogen replacement therapy and colorectal cancer risk in elderly women. Dis Colon Rectum. 1999;42:1300-1305.PubMedCrossRefGoogle Scholar
  91. 91.
    Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995;87:517-523.PubMedCrossRefGoogle Scholar
  92. 92.
    Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med. 1999;8:1155-1166.PubMedCrossRefGoogle Scholar
  93. 93.
    Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 2000;60:245-248.PubMedGoogle Scholar
  94. 94.
    Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res. 2001;61:632-640.PubMedGoogle Scholar
  95. 95.
    Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA. 2004;101:1566-1571.PubMedCrossRefGoogle Scholar
  96. 96.
    Martineti V, Picariello L, Tognarini I, et al. ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Relat Cancer. 2005;12:455-469.PubMedCrossRefGoogle Scholar
  97. 97.
    Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer. 2003;39:1251-1258.PubMedCrossRefGoogle Scholar
  98. 98.
    Lai JC, Cheng YW, Chiou HL, Wu MF, Chen CY, Lee H. Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer. Int J Cancer. 2005;117:974-980.PubMedCrossRefGoogle Scholar
  99. 99.
    Jacobsen BK, Vollset SE, Kvale G. Do reproductive factors influence colorectal cancer survival? J Clin Epidemiol. 1995;48:1119-1122.PubMedCrossRefGoogle Scholar
  100. 100.
    Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev. 1996;5:779-784.PubMedGoogle Scholar
  101. 101.
    Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991-1004.PubMedCrossRefGoogle Scholar
  102. 102.
    Miyake Y, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2006;24:519-523.PubMedCrossRefGoogle Scholar
  103. 103.
    Buchel E, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol. 2002;97:3160-3165.PubMedCrossRefGoogle Scholar
  104. 104.
    Heneghan MA, Norris SM, O’Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut. 2001;48:97-102.PubMedCrossRefGoogle Scholar
  105. 105.
    Kramer A, Sommer D, Hahn EG, Riecken EO. German experimental hepatitis B vaccine–influence of variation of dosage schedule, sex and age differences on immunogenicity in health care workers. Klin Wochenschr. 1986;64:688-694.PubMedCrossRefGoogle Scholar
  106. 106.
    Shimizu I, Kohno N, Tamaki K, et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007;13:4295-4305.PubMedGoogle Scholar
  107. 107.
    Inoue G, Horiike N, Michitaka K, Onji M. Hepatitis C virus clearance is prominent in women in an endemic area. J Gastroenterol Hepatol. 2000;15:1054-1058.PubMedCrossRefGoogle Scholar
  108. 108.
    Bakr I, Rekacewicz C, El Hosseiny M, et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut. 2006;55:1183-1187.PubMedCrossRefGoogle Scholar
  109. 109.
    Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol. 2007;21:447-451.PubMedGoogle Scholar
  110. 110.
    Schott E, Witt H, Hinrichsen H, et al. Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. J Hepatol. 2007;46:372-380.PubMedCrossRefGoogle Scholar
  111. 111.
    Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut. 2001;49:423-430.PubMedCrossRefGoogle Scholar
  112. 112.
    Paladino N, Fainboim H, Theiler G, et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol. 2006;80: 9144-9150.PubMedCrossRefGoogle Scholar
  113. 113.
    Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.CrossRefGoogle Scholar
  114. 114.
    Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998;93:1867-1872.PubMedCrossRefGoogle Scholar
  115. 115.
    Allison J, Herrinton LJ, Liu L, Yu J, Lowder J. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol. 2008;6:999-1003.PubMedCrossRefGoogle Scholar
  116. 116.
    Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet. 2004;270:79-85.PubMedCrossRefGoogle Scholar
  117. 117.
    Habal FM, Ravindran NC. Management of inflammatory bowel disease in the pregnant patient. World J Gastroenterol. 2008;14:1326-1332.PubMedCrossRefGoogle Scholar
  118. 118.
    Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn’s disease: a prospective cohort study. Gut. 1999;45:218-222.PubMedCrossRefGoogle Scholar
  119. 119.
    Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103: 1193-1196.PubMedCrossRefGoogle Scholar
  120. 120.
    Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Clin Liver Dis. 2004;8:283-300.PubMedCrossRefGoogle Scholar
  121. 121.
    Su FH, Chen JD, Cheng SH, Lin CH, Liu YH, Chu FY. Seroprevalence of hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national hepatitis-B vaccination program. J Med Virol. 2007;79:138-143.PubMedCrossRefGoogle Scholar
  122. 122.
    Garly ML, Jensen H, Martins CL, et al. Hepatitis B vaccination associated with higher female than male mortality in Guinea-bissau: an observational study. Pediatr Infect Dis J. 2004;23:1086-1092.PubMedGoogle Scholar
  123. 123.
    Morrey JD, Korba BE, Sidwell RW. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection. Antivir Ther. 1998;3:59-68.PubMedGoogle Scholar
  124. 124.
    Sezaki H, Suzuki F, Kawamura Y, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009;54:1317-1324.PubMedCrossRefGoogle Scholar
  125. 125.
    Kogure T, Ueno Y, Fukushima K, et al. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol. 2008;14:7225-4230.PubMedCrossRefGoogle Scholar
  126. 126.
    Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477.PubMedCrossRefGoogle Scholar
  127. 127.
    Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 2000;32:1131-1137.PubMedCrossRefGoogle Scholar
  128. 128.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.PubMedCrossRefGoogle Scholar
  129. 129.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.PubMedCrossRefGoogle Scholar
  130. 130.
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.PubMedGoogle Scholar
  131. 131.
    Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127:1724-1732.PubMedCrossRefGoogle Scholar
  132. 132.
    McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.PubMedCrossRefGoogle Scholar
  133. 133.
    Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, et al. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop. 2010;43:217-223.PubMedCrossRefGoogle Scholar
  134. 134.
    Northup PG, Pruett TL, Stukenborg GJ, Berg CL. Survival after adult liver transplantation does not correlate with transplant center case volume in the MELD era. Am J Transplant. 2006;6:2455-2462.PubMedCrossRefGoogle Scholar
  135. 135.
    Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.PubMedCrossRefGoogle Scholar
  136. 136.
    Cholongitas E, Shusang V, Marelli L, et al. Review article: renal function assessment in cirrhosis – difficulties and alternative measurements. Aliment Pharmacol Ther. 2007;26:969-978.PubMedCrossRefGoogle Scholar
  137. 137.
    Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis. 2003;41:269-278.PubMedCrossRefGoogle Scholar
  138. 138.
    Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med. 1988;39:465-490.PubMedCrossRefGoogle Scholar
  139. 139.
    Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. J Hepatol. 2011;54(3):462-470.PubMedCrossRefGoogle Scholar
  140. 140.
    Cholongitas E, Marelli L, Kerry A, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores – a systematic bias. Am J Transplant. 2007;7:685-692.PubMedCrossRefGoogle Scholar
  141. 141.
    Huo SC, Huo TI, Lin HC, et al. Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation. 2007;84:1406-1412.PubMedCrossRefGoogle Scholar
  142. 142.
    Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. JAMA. 2008;300:2371-2378.PubMedCrossRefGoogle Scholar
  143. 143.
    Axelrod DA, Pomfret EA. Race and sex disparities in liver transplantation: progress toward achieving equal access? JAMA. 2008;300:2425-2426.PubMedCrossRefGoogle Scholar
  144. 144.
    Marino IR, Doyle HR, Aldrighetti L, et al. Effect of donor age and sex on the outcome of liver transplantation. Hepatology. 1995;22:1754-1762.PubMedGoogle Scholar
  145. 145.
    Rustgi VK, Marino G, Halpern MT, Johnson LB, Umana WO, Tolleris C. Role of gender and race mismatch and graft failure in patients undergoing liver transplantation. Liver Transpl. 2002;8:514-518.PubMedCrossRefGoogle Scholar
  146. 146.
    Zeier M, Dohler B, Opelz G, Ritz E. The effect of donor gender on graft survival. J Am Soc Nephrol. 2002;13:2570-2576.PubMedCrossRefGoogle Scholar
  147. 147.
    Lehner F, Becker T, Klempnauer J, Borlak J. Gender-incompatible liver transplantation is not a risk factor for patient survival. Liver Int. 2009;29:196-202.PubMedCrossRefGoogle Scholar
  148. 148.
    Brooks BK, Levy MF, Jennings LW, et al. Influence of donor and recipient gender on the outcome of liver transplantation. Transplantation. 1996;62:1784-1787.PubMedCrossRefGoogle Scholar
  149. 149.
    Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.PubMedCrossRefGoogle Scholar
  150. 150.
    Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology. 1993;105:1057-1060.PubMedGoogle Scholar
  151. 151.
    Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology. 1998;114:23-28.PubMedCrossRefGoogle Scholar
  152. 152.
    Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut. 1981;22:445-451.PubMedCrossRefGoogle Scholar
  153. 153.
    Lucey MR, Neuberger JM, Williams R. Primary biliary cirrhosis in men. Gut. 1986;27:1373-1376.PubMedCrossRefGoogle Scholar
  154. 154.
    Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:2051-2057.PubMedCrossRefGoogle Scholar
  155. 155.
    Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257-265.PubMedCrossRefGoogle Scholar
  156. 156.
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.PubMedCrossRefGoogle Scholar
  157. 157.
    Zarski JP, Marcellin P, Leroy V, et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol. 2006;45:355-360.PubMedCrossRefGoogle Scholar
  158. 158.
    Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46.PubMedCrossRefGoogle Scholar
  159. 159.
    Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut. 2003;52:574-579.PubMedCrossRefGoogle Scholar
  160. 160.
    Bissell DM. Sex and hepatic fibrosis. Hepatology. 1999;29:988-989.PubMedCrossRefGoogle Scholar
  161. 161.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-832.PubMedCrossRefGoogle Scholar
  162. 162.
    Tangkijvanich P, Mahachai V, Suwangool P, Poovorawan Y. Gender difference in clinicopathologic features and ­survival of patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10:1547-1550.PubMedGoogle Scholar
  163. 163.
    Ng IO, Ng M, Fan ST. Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am J Gastroenterol. 1997;92:1355-1358.PubMedGoogle Scholar
  164. 164.
    Ng IO, Ng MM, Lai EC, Fan ST. Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach. Cancer. 1995;75:18-22.PubMedCrossRefGoogle Scholar
  165. 165.
    El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62-65.PubMedCrossRefGoogle Scholar
  166. 166.
    Dohmen K, Shigematsu H, Irie K, Ishibashi H. Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol. 2003;18:267-272.PubMedCrossRefGoogle Scholar
  167. 167.
    Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862.PubMedCrossRefGoogle Scholar
  168. 168.
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459.PubMedCrossRefGoogle Scholar
  169. 169.
    Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007;317:124-127.PubMedCrossRefGoogle Scholar
  170. 170.
    Persson PG, Karlen P, Bernell O, et al. Crohn’s disease and cancer: a population-based cohort study. Gastroenterology. 1994;107:1675-1679.PubMedGoogle Scholar
  171. 171.
    Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990;336:357-359.PubMedCrossRefGoogle Scholar
  172. 172.
    Soderlund S, Granath F, Brostrom O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138:1697-1703.PubMedCrossRefGoogle Scholar

Additional References

  1. 173.
    Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis. 2006;10:697-715.PubMedCrossRefGoogle Scholar
  2. 174.
    Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology. 2009;50:671-673.PubMedCrossRefGoogle Scholar
  3. 175.
    Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54:295-308.PubMedCrossRefGoogle Scholar
  4. 176.
    Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989;10:1-7.PubMedCrossRefGoogle Scholar
  5. 177.
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.PubMedCrossRefGoogle Scholar
  6. 178.
    Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg. 1997;185:55-59.PubMedGoogle Scholar
  7. 179.
    Krawitt EL. Autoimmune hepatitis. N Engl J Med. 1996;334:897-903.PubMedCrossRefGoogle Scholar
  8. 180.
    Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745.PubMedCrossRefGoogle Scholar
  9. 181.
    Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009;50:291-308.PubMedCrossRefGoogle Scholar
  10. 182.
    Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682-1683.PubMedCrossRefGoogle Scholar
  11. 183.
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225-1241.PubMedCrossRefGoogle Scholar
  12. 184.
    Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol. 1998;28:945-950.PubMedCrossRefGoogle Scholar
  13. 185.
    Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-1466.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  1. 1.Sheila Sherlock Liver CentreRoyal Free HospitalLondonUK

Personalised recommendations